Local in�ammation is a prominent characteristic of snakebite wound, and snake-venom phospholipase A 2 s (PLA 2 s) are some of the main component that contribute to accumulation of in�ammatory cells. However, the action of an R49 PLA 2 s, promutoxin from Protobothrops mucrosquamatus venom, on mast-cell accumulation has not been previously examined. Using a mouse peritoneal model, we found that promutoxin can induce approximately-6-fold increase in mast-cell accumulation, and the response lasts at least for 16 h. e promutoxin-induced mast cell accumulation was inhibited by cyproheptadine, terfenadine, and Ginkgolide B, indicating that histamine and platelet-activating factor (PAF) is likely to contribute to the mast-cells accumulation. Preinjection of antibodies against adhesion molecules ICAM-1, CD18, CD11a, and L-selectin showed that ICAM-1, and CD18, CD11a are key adhesion molecules of promutoxin-induced mast-cell accumulation. In conclusion, promutoxin can induce accumulation of mast cells, which may contribute to snake-venom wound.
Introduction
snake-venom phospholipase A 2 s (PLA 2 s) are low-molecularweight (13,000-14,000 Da), secretory phospholipases containing seven disul�de bonds. Usually, the PLA 2 s from Crotalidae or Viperidae venom are divided into two major groups: the Asp-49 PLA 2 s (D49 PLA2s) and Lys-49 PLA 2 s (K49 PLA 2 s), and several minor groups: Ser-49 PLA 2 s (S49 PLA 2 s) [1] [2] [3] , Asn-49 PLA 2 s (N49 PLA 2 s) [4, 5] , and Arg-49 PLA 2 s (R49 PLA 2 s) [6] [7] [8] . Besides the digestive function, snake PLA 2 s exhibit several other pharmacological properties including antiplatelet [9, 10] , anticoagulant [11] , hemolytic [9] , neurotoxic (presynaptic) [12] , and myotoxic [13] [14] [15] properties. ey have also been involved in various in�ammatory processes such as edema, in�ammatory cell in�ltration, and mast-cell activation [15] [16] [17] [18] [19] [20] .
Mast cells are primarily located in mucosal and perivascular areas of various tissues, which play an important role in body-defense processes. Mast cells can be activated by snake-venom and release carboxypeptidase A and possibly other proteases, which can degrade venom components [21, 22] . Several snake-venom PLA 2 s were reported to be able to activate the rat mast cells and to induce microvascular leakage and in�ammatory-cell accumulation at the sites of in�ammation [15] [16] [17] [18] [19] [20] . Our previous studies showed that TM-N49, an N49 PLA 2 puri�ed from Protobothrops mucrosquamatus venom, induces skin edema and mast-cell activation and accumulation [23] , and promutoxin, an R49 PLA 2 puri�ed from the same snake, can activate mast cells and induce skin edema [24] . Both TM-N49 and promutoxin are devoid of catalytic activity and are thought to contribute to Protobothrops mucrosquamatus venom toxicity [5, 8] . Moreover, both TM-N49 and promutoxin are potent stimuli for induction of neutrophil, lymphocyte, macrophage, and eosinophil accumulation in the mouse peritoneum [25] . ese observations suggested that the two novel subgroups of group II PLA 2 may contribute to the in�ammatory process caused by snake-venom poisoning. However, the ability of R49 PLA 2 on induction of mast-cell accumulation has not yet been reported. In the present study, we investigated the mechanisms of promutoxin-induced mast-cell accumulation. 
Materials and Methods

Puri�cation of Promutoxin. Promutoxin was isolated from
Protobothrops mucrosquamatus crude venom following the procedures described previously [8] . Brie�y, the lyophilized venom (1.5 g) was dissolved in 20 mL of 0.05 M sodium phosphate buffer (pH 5.8) before being loaded on an SP-Sephadex C-25 column. e absorbed proteins were eluted with a linear gradient (0-0.8 M NaCl). Peak 7 was collected and loaded on Superdex 75 column in 25 mM sodium phosphate buffer (pH 5.8 with 0.15 M NaCl). e main peak was collected, and then loaded on a reversephase C 18 high-performance liquid chromatography (HPLC) (Waters Corporation, Milford, MA, USA). e main peak fraction, representing the puri�ed promutoxin, was pooled, lyophilized, and stored at -20 ∘ C. Protein concentration was determined by using a Coomassie Plus assay kit with BSA as standard. e PLA 2 activity was routinely assayed by a titration method using egg yolk as substrate [26] and by a colorimetric assay using L-phosphatidylcholine as substrate [27] . Honey-bee PLA 2 was employed as positive control.
Induction of Mast-Cell Accumulation.
Various doses of promutoxin, BSA or normal saline were injected in 0.5 mL volumes into the peritoneum of male BALB/c mice, whose abdominal skin was swabbed with 70% ethanol, a group of 6 mice for each dose. is model was adapted from that described by omas and colleagues [28] , which complied with the European Community guidelines for use of experimental animals. At 10 min, 2 h, 6 h, or 16 h following injection, animals were sacri�ced by inhalation of carbon dioxide, and their peritoneal lavages were collected following a standardized procedure with 5 mL normal saline. Aer centrifugation at 500 g for 10 min at 4 ∘ C, supernatants were collected and stored at −40 ∘ C until use, and cells were resuspended in 1 mL of MEM. e total cell numbers were determined by enumerating them with an Improved Neubauer haemocytometer aer being stained with 0.1% trypan blue. For the differential cell counting, cytocentrifuge preparations were made, air dried, and stained with modi�ed Wright's stain. Differential cell counts were performed for a minimum of 500 cells. e results were expressed as absolute numbers of each cell type per mouse peritoneum.
For the experiments investigating mast-cell-migration mechanisms, groups of mice were pretreated intravenously (tail vein injection) with monoclonal antibodies against the adhesion molecules L-selectin, CD11a, CD18, and ICAM-1 (all at a dose of 1 mg⋅kg −1 ) [29] [30] [31] , respectively, for 30 min before intraperitoneal injection of 5 g of promutoxin. Control animals received an equivalent dose of the corresponding normal rat or hamster IgG isotype control. At 6 h following injection, the mice were sacri�ced and their peritoneal lavages were processed as described above.
To investigate potential mechanisms involved in promutoxin-induced mast-cell accumulation, several anti-in�ammatory compounds including cyproheptadine (2 mg⋅kg −1 ) [17] , terfenadine (3 mg⋅kg −1 ) [32, 33] , ginkgolide B (5 mg⋅kg −1 ) [34] , and quinacrine (10 mg⋅kg −1 ) [35] were coinjected into the peritoneum of mice with promutoxin (5 g per mouse). Control animals received an injection of drug alone. At 6 h following injection, mice were sacri�ced and their peritoneal lavages were processed as described above.
Statistical Analysis.
Data are shown as mean ± SE for the number of experiments indicated, and ANOVA followed by Tukey's tests were used for statistical comparison of the data. In all analyses, was taken as statistically signi�cant.
Results
Puri�cation and Characteri�ation of Promutoxin.
Approximately 25 mg of promutoxin was obtained from 1.5 g Protobothrops mucrosquamatus crude venom following the procedures described above. e purity of the PLA 2 was at least 98% as assessed by SDS-PAGE, HPLC, and mass spectrometry analysis [24] .
Induction of Mast-Cell Accumulation by Promutoxin.
As early as 10 min following injection, 5 g of promutoxin was able to induce signi�cant mast-cell accumulation in the peritoneum of mice. e mast-cell accumulation appeared to last for 16 h (Figure 1) . Approximately, up to 6-fold increase in mast-cell numbers was achieved at 16 h following injection (Figure 1 ).
�.�. ��ects o� Anti-�n�ammato�� Com�ounds and �loc�in�
Antibodies on Mast-Cell Accumulation. When coinjected, ginkgolide B, cyproheptadine and terfenadine inhibited 35.9, 71.3, and 92.6% promutoxin-induced mast-cell accumulation in the peritoneum of mice, respectively. However, quinacrine did not signi�cantly alter the extent of promutoxin-induced mast-cell accumulation. At the dose tested, ginkgolide B, cyproheptadine, terfenadine, and quinacrine by themselves failed to induce mast-cell accumulation in the peritoneum of mice (Table 1) .
Intravenous injection of monoclonal antibodies against CD18, ICAM-1, and CD11a 30 min prior to intraperitoneal injection of the PLA 2 -blocked promutoxin-induced mastcell accumulation by 87.2, 76.7, and 53.8%, respectively. Monoclonal antibody against L-selectin failed to diminish promutoxin-induced mast-cell accumulation. Normal rat and hamster IgG-isotype controls tested had little effect on promutoxin-induced mast-cell accumulation (Table 2 ).
Discussion
It is found for the �rst time that promutoxin, a novel member of a minor subgroup (R49 PLA 2 ) of snake-venom group II PLA 2 s, can induce mast-cell accumulation. e observation supports our previous �nding that N49 PLA 2 , another minor subgroup of snake-venom group II PLA 2 s [23] can induce mast-cell accumulation. Obviously, promutoxin does not induce mast-cell accumulation in a concentrationdependent manner [24] . We previously found that promutoxin could activate mast-cells. e reduction of mast-cell number induced by promutoxin in higher doses may be due to the activation of accumulated mast-cells by promutoxin.
Ginkgolide B, a PAF antagonist, inhibited more than 35.9% promutoxin-induced mast-cell migration, indicating that PAF is likely involved in mast-cell migration by promutoxin. is result appears to agree with a previous work which found that PAF may contribute to mast-cell migration induced by TM-N49 [23] . Inhibition of 71.3 and 92.6% promutoxin-induced mast-cell accumulation by cyproheptadine, a histamine/5-HT antagonist, and terfenadine a selective histamine-H 1 -receptor antagonist, implies that histamine is likely to be involved in the above event through its H 1 receptor. Indeed, we have found previously that promutoxin can activate mast cells to release histamine [24] and anticipate herein that released histamine then elicits mast-cell migration. e fact that terfenadine inhibited promutoxin-provoked mast-cell recruitment to a greater extent than cyproheptadine further implies the selectivity of histamine receptor involved. It was found that snake-venom promutoxin could induce mast-cell accumulation even at 10 min following injection, but the number of lymphocyte, macrophage, eosinophil, and neutrophil migration was not altered at 10 min following injection of promutoxin [25] . It seemed the accumulation of neutrophils, lymphocyte, macrophage, and eosinophil induced by promutoxin could be a secondary event, in which accumulated mast cells are activated by promutoxin and release their chemoattractant factors such as serine proteinases [36, 37] , histamine, and PAF to recruit in�ammatory cells.
ICAM-1 appears to be a key adhesion molecule of promutoxin-induced mast-cell accumulation as an antibody against ICAM-1 blocked more than 76.7% of the in�uence of promutoxin on the cell migration. ICAM-1 involved in lymphocyte [38] , macrophage [39] , eosinophil [40, 41] and mast-cell accumulation [23] has been reported previously, which may support our current observations. An antibody against CD11a (LFA-1) blocked more than 53.8% promutoxin-induced mast-cell accumulation, indicating that CD11a plays an important role in the migration of mast cells, which is consistent with previous reports that TM-N49-induced mast-cell accumulation is mediated by CD18, CD11a, and ICAM-1 [23] . As expected, antibody against CD18 blocked more than 87.2% promutoxin-induced mastcell accumulation in the present study. ough L-selectin is involved in the neutrophil and eosinophil accumulation provoked by promutoxin, it seemed that L-selectin is not involved in the promutoxin-induced mast-cell accumulation.
Promutoxin, as a novel member of minor subgroup of PLA 2 , is an enzymatically inactive enzyme. It induced mastcell accumulation via a PAF, and histamine H 1 receptordependent mechanism, and through a CD11a/CD18-and ICAM-1-associated adhesion pathway. Accumulated mast cells may contribute to snake-venom wound.
